By uniting diverse data and researchers working on neurodegenerative disorders globally, we seek to contribute to the advancement of the diagnosis and treatment of conditions impacting over 57 million people in need.
To date, the GNPC has gathered over 40,000 patient samples from over 20 international research groups to create our V1 Harmonized Data Set (HDS), comprising nearly 300,000,000 unique protein measurements. The HDS spans multiple neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Company Details
- Founded
- -
- Industry
- Public Health
- NAICS
-
Administration of Public Health Programs
- Website
- https://www.neuroproteome.org/
- Keywords
- ANSWER ALS.
- Competitors
- AD-RIDDLE, CTAD Clinical Trials on Alzheimer's Disease, The Swedish BioFINDER study, Gates Ventures, Alzheimer's Disease Data Initiative, European Platform for Neurodegenerative Diseases (EPND), Fundación Pasqual Maragall, Ace Alzheimer Center Barcelona, Drug Intervention Institute Inc., ANSWER ALS.
Global Neurodegeneration Proteomics Consortium Questions
Global Neurodegeneration Proteomics Consortium's website is https://www.neuroproteome.org/
Global Neurodegeneration Proteomics Consortium's LinkedIn profile is https://www.linkedin.com/company/neuro-proteome
Global Neurodegeneration Proteomics Consortium's industry is
Public Health
Global Neurodegeneration Proteomics Consortium's top competitors are
Ad-Riddle,
Ctad Clinical Trials On Alzheimer's Disease,
The Swedish Biofinder Study,
Gates Ventures,
Alzheimer's Disease Data Initiative,
European Platform For Neurodegenerative Diseases (Epnd),
Fundación Pasqual Maragall,
Ace Alzheimer Center Barcelona,
Drug Intervention Institute Inc.,
Answer Als.
Global Neurodegeneration Proteomics Consortium's categories are Public Health
Global Neurodegeneration Proteomics Consortium's founding year is 2023
